[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma

RJ Motzer, NM Tannir, DF McDermott… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a …

RJ Motzer, BI Rini, DF McDermott, OA Frontera… - The Lancet …, 2019 - thelancet.com
Background In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab
showed superior efficacy over sunitinib in patients with previously untreated intermediate …

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma …

DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee… - European urology, 2014 - Elsevier
Background The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …

[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 …

L Albiges, NM Tannir, M Burotto, D McDermott… - ESMO open, 2020 - Elsevier
Purpose To report updated analyses of the phase III CheckMate 214 trial with extended
minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab …

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long‐term follow‐up of the randomized, open‐label, phase 3 …

RJ Motzer, B Escudier, S George, HJ Hammers… - Cancer, 2020 - Wiley Online Library
Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in
patients with advanced renal cell carcinoma (aRCC) along with improved safety and …

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

RJ Motzer, DF McDermott, B Escudier, M Burotto… - Cancer, 2022 - Wiley Online Library
Background Conditional survival estimates provide critical prognostic information for
patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional …

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

AJ Armstrong, S Halabi, T Eisen, S Broderick… - The Lancet …, 2016 - thelancet.com
Background Non-clear cell renal cell carcinomas are histologically and genetically diverse
kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We …

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label …

DJ Khalaf, M Annala, S Taavitsainen, DL Finch… - The Lancet …, 2019 - thelancet.com
Background Abiraterone acetate plus prednisone and enzalutamide are both used for the
treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best …

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

A Amin, ER Plimack, JR Infante, MS Ernstoff, BI Rini… - 2014 - ascopubs.org
5010 Background: Antiangiogenic agents sunitinib (S) and pazopanib (P) are SOC for
mRCC, but new therapies are needed as pts advance through therapy with limited survival …

Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC …

N Kroeger, W Xie, JL Lee, GA Bjarnason, JJ Knox… - Cancer, 2013 - Wiley Online Library
BACKGROUND This study aimed to apply the International mRCC Database Consortium
(IMDC) prognostic model in metastatic non–clear cell renal cell carcinoma (nccRCC). In …